Drug Trial Radar · NCT04317885
A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects
Last checked: Nov 20, 2026Latest source record: May 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Nov 5, 2019
Primary completion
Jun 30, 2023
Study completion Dec 30, 2023
Sponsor
- Lead sponsor
- Shanghai Tongji Hospital, Tongji University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shanghai AbelZeta Ltd.
- First posted
- Mar 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of C-CAR039 in treatment of relapsed or refractory NHL patients
Conditions
- Non-Hodgkin's B-cell Lymphoma
Interventions
Prizloncabtagene AutoleucelBiological
Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse eventsTime frame: Up to 12 weeks after C-CAR039 infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Tongji Hospital, Tongji University School of Medicine
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.